

Michael Lattanzi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5506529/michael-lattanzi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10
papers

95
citations

6
h-index

9
g-index

11
ext. papers

160
ext. citations

4.6
avg. IF

2.8
L-index

#	Paper	IF	Citations
10	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101485	2.2	2
9	The emerging role of antibody-drug conjugates in urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 551-561	3.5	9
8	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. <i>Cancer Immunology Research</i> , 2020 , 8, 70-80	12.5	19
7	Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma. <i>Current Oncology Reports</i> , 2019 , 21, 24	6.3	13
6	Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 180-188	9.7	37
5	Single cell analysis of urothelial carcinoma (UC) liver metastases identifies epithelial-mesenchymal transition (EMT) as a potential mechanism of resistance to immunotherapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16018-e16018	2.2	
4	Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis 2018 , 6, 38		6
3	Association of upregulation of serine and one carbon metabolism genes with shorter recurrence-free and overall survival in urothelial bladder cancer (UBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 477-477	2.2	
2	Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy 2018 , 6, 97		9
1	Primary melanoma histologic subtype (HS) impacts melanoma specific survival (MSS) and response to systemic therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9577-9577	2.2	